<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE abs SYSTEM "SNPPhentA.dtd">
<abstract ABSTRACTID="1004" TEXT="OBJECTIVE: Opioids are frequently used during mechanical ventilation for severe viral infection in infancy. Opioid receptors have immunomodulatory properties, but nothing is known about their antiviral effects. We therefore aimed to investigate the role of opioid receptors in virus-induced airwayinflammation. METHODS: Two single nucleotide polymorphisms in OPRM1 and OPRD1 were genotyped in 465 infants with severe respiratory syncytialvirus infection and 930 control subjects. Subsequently, the mechanism by which opioid receptors affect clinical outcome in respiratory syncytial virusbronchiolitis was studied in BALB/c mice. Animals were injected daily with nalmefene, a nonselective opioid receptor antagonist, and infected by intranasal inoculation of respiratory syncytial virus 24 hrs after the first dose of nalmefene. The potential therapeutic effect of pharmaceutical opioids was studied using µ (DAMGO), κ (U50488), and Δ (DPDPE) opioid receptor agonists 48 hrs after infection. RESULTS: In our human study, the A118G singlenucleotide polymorphism rs1799971 was associated with respiratory syncytial virus disease severity (p = 0.015). In mice, nalmefene treatment increasedviral titers and was associated with more pronounced weight loss. Increased viral replication was associated with increased levels of cytokines andchemokines in the bronchoalveolar lavage fluid, enhanced bronchoalveolar cellular influx, and exaggerated lung pathology. Pharmaceutical opioids, in particular DPDPE, did not affect viral replication. They did induce a decreased influx of neutrophils, but an increased influx of lymphocytes and monocytesinto the bronchoalveolar lumen during respiratory syncytial virus infection. CONCLUSIONS: Using a human study and an experimental model, we show that opioid receptor signaling has a potential beneficial role in the outcome of respiratory viral disease. We show that opioid receptor signaling is required to control respiratory syncytial virus replication and thereby to control disease severity. However, we also show that caution is required before using pharmaceutical opioids as anti-inflammatory or antiviral treatment of patients with viral respiratory infection.">
	<sentence ID="1004_0" START="992" END="1148">
		<snp ID="0" START="1061" END="1070" TEXT="rs1799971"/>
		<phenotype ID="0" START="1091" END="1148" text="respiratory syncytial"/>
		<pair PAIRID="0" PHENOTYPEID="0" SNPID="0" ASSOCIATION="positive" CONFIDENCE="weak"/>
	</sentence>
</abstract>
